

Curriculum Vitae - Dr Tiago Reis Marques

PERSONAL DETAILS			
Name	Tiago Reis Marques		
Date of birth	14/09/1976		
Nationality	Portuguese		
Marital status	Single		
Languages	Portuguese native. Fluent in English and Spanish.		
Address	Flat 1, n°97B Earls Court Road W8 6QH London	Mobile: e-mail:	+ 44 7766975702 tiago.marques@kcl.ac.uk

QUALIFICATIONS		
PhD	Institute of Psychiatry, Kings College - London	2008–2012
Medical Degree	Coimbra University Medical School - Portugal	1995–2001

CURRENT EMPLOYER		
Imperial College	Senior Clinical Research Fellow Institute of Clinical Sciences Faculty of Medicine	Mar 15 – On going

PREVIOUS EMPLOYMENT HISTORY		
Post-Doc Clinical Research Worker	Division of Psychosis Studies Institute of Psychiatry, King's College London	Jan 13 – Mar 15
PhD student	Division of Psychosis Studies Institute of Psychiatry, King's College London	Mar 08 – Dec 12
Residency in Psychiatry	Coimbra University Hospital Portugal	Jan 04 – Jan 10
Visiting Medical Doctor	Mayo Clinic Rochester, Minnesota USA	Sep 01–Mar 02

SPECIALIST CERTIFICATION (IN PSYCHIATRY)	
Specialist Register – General Psychiatry: UK	2013
Fellow of the Portuguese College of Psychiatrists: Portugal	2012

Licence to Practice		
UK	Independent License (GMC – 700395)	2008
Portugal	General Licence (OM – 41283)	2004

AWARDS AND GRANTS	
Total grant income: £1,961,940	
2016 – Medical Research Council Experimental Medicine Grant: Targeting Neuroinflammation in Schizophrenia (Co-Applicant; PI: Oliver Howes) (£1,035,589)	
2015 – Young Investigator Award, 15 th International Congress of Schizophrenia Research Conference (ICOSR)	
2014 – Medical Research Council Research Grant: Beyond dopamine receptors in Schizophrenia - evaluating the role of Phosphodiesterase 10A in disease and treatment using PET imaging (Co-Applicant; PI: Shitij Kapur) (£867,057)	
2014 – Royal Society of Medicine Psychiatry Prize (2 nd place)	
2013 – BRC Travel Award for the 14 th International Congress of Schizophrenia Research (ICOSR)	
2012 – Young Investigator Award NARSAD grant (\$60000)	
2008 – Pump Priming award - Biomedical Research Council: "White matter integrity as a biomarker of treatment response: a DTI study" (£11,000)	
2008 – Best poster award in the Portuguese National Congress of Psychiatry: "Thalamus Volume in First Episode Schizophrenia and Healthy Controls"	

2005 – Best poster award in the Portuguese National Congress of Psychiatry: “Brain perfusion (SPECT) in heroin addicts patients”

2005 – Portuguese Young Psychiatry Award

PUBLICATIONS

Scopus – H index: 17; Citations: 924

Google scholar – H index: 19; Citations: 1466

ResearchGate – H index: 18; Citations: 1076

Publications:

1. Sexual dysfunction and central obesity in patients with first episode psychosis.

Theleritis C, Bonaccorso S, Habib N, Stahl D, Gaughran F, Vitoratou S, Atakan Z, Kolliakou A, Gardner Sood P, Dazzan P, **Marques TR**, McGuire P, Greenwood K, Eberhard J, Breedvelt J, Ferracuti S, Di Forti M, Murray RM, Smith S.

Eur Psychiatry. 2017 Feb 12;42:1-7.

2. Connectomic correlates of response to treatment in first-episode psychosis.

Crossley NA, **Marques TR***, Taylor H, Chaddock C, Dell'Acqua F, Reinders AA, Mondelli V, DiForti M, Simmons A, David AS, Kapur S, Pariante CM, Murray RM, Dazzan P.

Brain. 2017 Feb;140(Pt 2):487-496.

***co-joint first author**

3. Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study.

Goozee R, O'Daly O, Handley R, **Reis Marques T**, Taylor H, McQueen G, Hubbard K, Pariante C, Mondelli V, Reinders AA, Dazzan P.

Hum Brain Mapp. 2016 Dec 23.

4. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, **Reis Marques T**, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU.

Am J Psychiatry. 2016 Dec 6

5. Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification.

Palaniyappan L, **Marques TR**, Taylor H, Mondelli V, Reinders AA, Bonaccorso S, Giordano A, DiForti M, Simmons A, David AS, Pariante CM, Murray RM, Dazzan P.

Schizophr Bull. 2016 Nov;42(6):1446-1456.

6. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, **Marques TR**, Garibaldi G, Kapur S.

Lancet Psychiatry. 2016 Nov 2.

7. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.

Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, Mondelli V, **Reis Marques T**, Pariante C, Dazzan P, Shergil SS, Howes OD, David AS, MacCabe JH, Gaughran F, Murray RM.

Psychol Med. 2016 Nov;46(15):3231-3240.

8. An examination of polygenic score risk prediction in individuals with first episode psychosis

Evangelos Vassos, Marta Di Forti, Jonathan Coleman, Conrad Iyegbe, Diana Prata, Jack Euesden, Charles Curtis, Anna Kolliakou, Olesya Ajnakina, Valeria Mondelli, **Tiago Reis Marques**, Poonam Gardner-Sood, Katherine J Aitchison, John Powell, Zerrin Atakan, Kathryn E Greenwood, Shubulade Smith^{2,10}, Khalida Ismail, Carmine Pariante, Fiona Gaughran², Paola Dazzan, Anthony S David, Cathryn M Lewis, Robin M Murray, Gerome Breen

Biol Psychiatry. 2016 Aug 6.

9. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Wilson H, Niccolini F, Haider S, **Marques TR**, Pagano G, Coello C, Natesan S, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M. *J Neurol Sci*. 2016 Sep 15;368:243-8.
10. Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Handley R, Mondelli V, Zelaya F, **Marques T**, Taylor H, Reinders AA, Chaddock C, McQueen G, Hubbard K, Papadopoulos A, Williams S, McGuire P, Pariante C, Dazzan P. *Schizophr Res*. 2016 Jul;174(1-3):99-105.
11. Phosphodiesterase 10A in Schizophrenia: A Positron Emission Tomography study using [11C]IMA107 **Tiago Reis Marques**, Sridhar Natesan, Ilan Rabiner, Oliver Howes, Flavia Niccolini, Marios Politis, Graham Serle, Roger Gunn, Shitij Kapur *Am J Psychiatry*. 2016 Jul 1;173(7):714-21
12. Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. Diggle CP, Sukoff Rizzo SJ, Popielek M, Hinttala R, Schülke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, **Marques TR**, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ. *Am J Hum Genet*. 2016 Apr 7;98(4):735-43.
13. Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain. Kapur S, **Marques TR**. *JAMA Psychiatry*. 2016 Feb 1;73(2):107-8.
14. Effect of high-potency cannabis on corpus callosum microstructure. Rigucci S, **Marques TR***, Di Forti M, Taylor H, Dell'Acqua F, Mondelli V, Bonaccorso S, Simmons A, David AS, Girardi P, Pariante CM, Murray RM, Dazzan P. *Psychol Med*. 2015 Nov 27:1-14
***co-joint first author**
15. A Neuroanatomical Signature for Schizophrenia Across Different Ethnic Groups. Gong Q, Dazzan P, Scarpazza C, Kasai K, Hu X, **Marques TR**, Iwashiro N, Huang X, Murray RM, Koike S, David AS, Yamasue H, Lui S, Mechelli A. *Schizophr Bull*. 2015 Nov;41(6):1266-75.
16. Career Satisfaction of Medical Residents in Portugal. Martins MJ, Láins I, Brochado B, Oliveira-Santos M, Teixeira PP, Brandão M, Cerqueira RJ, Castro-Ferreira R, Bernardes C, Menezes MN, Baptista BS, Ladeiras-Lopes R, Rei MC, Rosa GP, Martins JL, Mendonça Sanches M, Ferreira-Pinto MJ, Rato M, Costa e Silva M, Policiano C, Beato J, Barbosa-Breda J, Torres JP, Leal I, Rosa SA, Ribeiro BC, Costa FR, Palmela C, Gonçalves TC, Morais L, **Marques TR**. *Acta Med Port*. 2015 Mar-Apr;28(2):209-21
17. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. Niccolini F, Foltynie T, **Reis Marques T**, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini P, Politis M. *Brain*. 2015 Oct;138(Pt 10):3003-15.
18. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Niccolini F, Haider S, **Reis Marques T**, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Piccini P, Kapur S, Rabiner EA, Gunn RN, Tabrizi SJ, Politis M. *Brain*. 2015 Oct;138(Pt 10):3016-29.
19. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. McCutcheon R, Beck K, Bloomfield MA, **Marques TR**, Rogdaki M, Howes OD. *J Psychopharmacol*. 2015 Aug;29(8):892-7.
20. Association between the COMT gene and neurological abnormalities and poorer executive function in psychosis. Tosato S, Ira E, Russo M, Iyegbe C, Lasalvia A, Di Forti M, Morgan K, Bonetto C, Morgan C, De Rossi M, Nicolau

S, Chan RC, **Reis Marques T**, Collier DA, Reichenberg A, Murray RM, Tansella M, Ruggeri M, Dazzan P. Psychiatry Res. 2015 Dec 15;230(2):742-3.

21. The proportion of patients with first episode psychosis attributable to high potency cannabis use: the example of South London.

Marta Di Forti, Arianna Marconi, Elena Carra, Sara Fraietta, Antonella Trotta, Matteo Bonomo, Francesca Bianconi, Poonam Sood, Jennifer O'Connor, Manuela Russo, Simona A. Stilo, **Tiago Reis Marques**, Valeria Mondelli, Paola Dazzan, Carmine Pariante, Anthony S. David, Fiona Gaughran, Zerrin Atakan, Conrad Iyegbe, John Powell, Craig Morgan, Michael Lynksey, Robin M. Murray
Lancet Psychiatry. 2015 Mar;2(3):233-8.

22. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis.

Mondelli, Valeria, Ciufolini, Simone, Belvederi Murri, Martino, Bonaccorso, Stefania; Di Forti, Marta, Giordano, Annalisa; **Marques, Tiago**; Zunszain, Patricia; Morgan, Craig, Murray, Robin, Pariante, Carmine, Dazzan, Paola
Schizophr Bull. 2015 Mar 31.

23. Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study.

Goozee R, Reinders AA, Handley R, **Marques T**, Taylor H, O'Daly O, McQueen G, Hubbard K, Mondelli V, Pariante C, Dazzan P.
Schizophr Res. 2015 Mar 13.

24. The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach.

Beck K, McCutcheon R, Bloomfield MA, Gaughran F, **Reis Marques T**, MacCabe J, Selvaraj S, Taylor D, Howes OD.
Acta Psychiatr Scand. 2014 Dec;130(6):427-38.

25. Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users.

Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, **Reis Marques T**, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, Maccabe JH, Murray RM.
Schizophr Bull. 2014 Nov;40(6):1509-17.

26. How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses.

Marques TR, Levine SZ, Reichenberg A, Kahn R, Derks EM, Fleischhacker WW, Rabinowitz J, Kapur S.
Eur Neuropsychopharmacol. 2014 Aug;24(8):1279-88.

27. Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis.

Ajnakina O, Borges S, Di Forti M, Patel Y, Xu X, Green P, Stilo SA, Kolliakou A, Sood P, **Marques TR**, David AS, Prata D, Dazzan P, Powell J, Pariante C, Mondelli V, Morgan C, Murray RM, Fisher HL, Iyegbe C.
Front Psychiatry. 2014 Jul 17;5:84.

28. Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human.

Pliссon C, Weinzimmer D, Jakobsen S, Natesan S, Salinas C, Lin SF, Labaree D, Zheng MQ, Nabulsi N, **Marques TR**, Kapur S, Kawanishi E, Saijo T, Gunn RN, Carson RE, Rabiner EA.
J Nucl Med. 2014 Apr;55(4):595-601.

29. White matter integrity as a predictor of response to treatment in first episode psychosis.

Reis Marques T, Taylor H, Chaddock C, Dell'acqua F, Handley R, Reinders AA, Mondelli V, Bonaccorso S, Diforti M, Simmons A, David AS, Murray RM, Pariante CM, Kapur S, Dazzan P.
Brain. 2014 Jan;137(Pt 1):172-82.

30. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Chen L, Johnston JA, Kinon BJ, Stauffer V, Succop P, **Marques TR**, Ascher-Svanum H.
BMC Psychiatry. 2013 Nov 28;13:320

31. Social Disadvantage: Cause or Consequence of Impending Psychosis?

Stilo SA, Di Forti M, Mondelli V, Falcone AM, Russo M, O'Connor J, Palmer E, Paparelli A, Kolliakou A, Sirianni M, Taylor H, Handley R, Dazzan P, Pariante C, **Marques TR**, Zoccali R, David A, Murray RM, Morgan C.
Schizophr Bull. 2013 Nov;39(6):1288-95

32. Cortical Folding Defects as Markers of Poor Treatment Response in First-Episode Psychosis.

- Palaniyappan L, **Marques TR**, Taylor H, Handley R, Mondelli V, Bonaccorso S, Giordano A, McQueen G, Diforti M, Simmons A, David AS, Pariante CM, Murray RM, Dazzan P.
JAMA Psychiatry. 2013 Oct;70(10):1031-40
33. Wiffen BD, O'Connor JA, Gayer-Anderson C, **Reis Marques T**, McQueen G, Happé F, Murray RM, David AS.
"I am sane but he is mad": Insight and illness attributions to self and others in psychosis.
Psychiatry Res. 2013 May 30;207(3):173-8
34. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.
Handley R, Zelaya FO, Reinders AA, **Marques TR**, Mehta MA, O'Gorman R, Alsop DC, Taylor H, Johnston A, Williams S, McGuire P, Pariante CM, Kapur S, Dazzan P.
Hum Brain Mapp. 2013 Feb;34(2):272-82
35. Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users.
Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, **Marques TR**, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM.
Biol Psychiatry. 2012 Nov 15;72(10):811-6
36. Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients.
Hepgul N, Pariante CM, Dipasquale S, DiForti M, Taylor H, **Marques TR**, Morgan C, Dazzan P, Murray RM, Mondelli V.
Psychol Med. 2012 Sep;42(9):1893-901
37. Sexual dysfunction in people with prodromal or first-episode psychosis.
Marques TR, Smith S, Bonaccorso S, Gaughran F, Kolliakou A, Dazzan P, Mondelli V, Taylor H, Diforti M, McGuire PK, Murray RM, Howes OD.
Br J Psychiatry. 2012 Aug;201:131-6
38. The neuro/PsyGRID calibration experiment: Identifying sources of variance and bias in multicenter MRI studies.
Suckling J, Barnes A, Job D, Brennan D, Lymer K, Dazzan P, **Marques TR**, Mackay C, McKie S, Williams SR, Williams SC, Deakin B, Lawrie S.
Hum Brain Mapp. 2012 Feb;33(2):373-86
39. The different trajectories of antipsychotic response: Antipsychotics versus Placebo
Reis Marques T; Arenovich T; Agid O; Sajeev G; Muthén B; Chen L; Kinon B; Kapur S
Psychological Medicine, 2011 Jul;41(7):1481-8
40. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis.
Aas M, Dazzan P, Mondelli V, Touloupoulou T, Reichenberg A, Di Forti M, Fisher HL, Handley R, Hepgul N, **Marques T**, Miorelli A, Taylor H, Russo M, Wiffen B, Papadopoulos A, Aitchison KJ, Morgan C, Murray RM, Pariante CM.
Psychol Med. 2011 Mar;41(3):463-76.
41. Power calculations for multicenter imaging studies controlled by the false discovery rate.
Suckling J, Barnes A, Job D, Brennan D, Lymer K, Dazzan P, **Marques TR**, MacKay C, McKie S, Williams SR, Williams SC, Lawrie S, Deakin B.
Hum Brain Mapp. 2010 Aug;31(8):1183-95.
42. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis.
Mondelli V, Pariante CM, Navari S, Aas M, D'Albenzio A, Di Forti M, Handley R, Hepgul N, **Marques TR**, Taylor H, Papadopoulos AS, Aitchison KJ, Murray RM, Dazzan P.
Schizophr Res. 2010 Jun;119(1-3):75-8. Epub 2010 Jan 13.
43. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.
Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, Di Nicola M, Fisher H, Handley R, **Marques TR**, Morgan C, Navari S, Taylor H, Papadopoulos A, Aitchison KJ, Murray RM, Pariante CM.
Schizophr Res. 2010 Feb;116(2-3):234-42. Epub 2009 Sep 13.
44. Obsessive-compulsive disorder as a visual processing impairment.
Gonçalves OF, **Marques TR**, Lori NF, Sampaio A, Branco MC.
Med Hypotheses. 2010 Jan;74(1):107-9. Epub 2009 Aug 19.

45. High-potency cannabis and the risk of psychosis.

Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, **Marques TR**, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM.

Br J Psychiatry. 2009 Dec;195(6):488-91.

46. Brain blood flow SPET imaging in heroin abusers.

Botelho MF, Relvas JS, Abrantes M, Cunha MJ, **Marques TR**, Rovira E, Fontes Ribeiro CA, Macedo T.

Ann N Y Acad Sci. 2006 Aug;1074:466-77

TEACHING

2014 – on going: Invited Lecturer – MSc in Psychiatric Research (Institute of Psychiatry, Psychology and Neuroscience, King’s College, London)

2012 – on going: Invited Lecturer – MSc in Mental Health Studies (Institute of Psychiatry, Psychology and Neuroscience, King’s College, London)

2013 – 2015: Psychopharmacology module supervisor – MSc in Psychiatric Research (Institute of Psychiatry, Psychology and Neuroscience, King’s College, London)

2012 – 2015: Clinical advisor for 3rd and 4th years medical students (King’s College, London)

SUPERVISION

2015 – PhD student (2nd supervisor): "The role of Mu-Opioid receptor in schizophrenia"

2014 – MSc student: "The application of support vector machine learning to predict treatment response in first episode psychosis patients" (Student grade: Distinction)

2013 – MSc student: "A DTI Tractography Study of the Cingulum Bundle in First-Episode Psychosis" (Student grade: Merit)

2013 – MSc student: "The relationship between cannabis and white matter in First-Episode Psychosis" (Student grade: Pass)

2011 – MSc student: "A DTI tractography study of the Inferior Fronto-Occipital Fasciculus and the Inferior Longitudinal Fasciculus in first episode psychosis" (Student grade: Distinction)

2010 – MSc student: "Auditory hallucinations in first episode psychotic subjects: A diffusion tensor imaging study of the arcuate fasciculus" (Student grade: Merit)